Background:
Cervical cancer is the most common gynecologic malignant tumor .The occurrence and
progression of cervical carcinoma is firmly relevant to HPV (Human papilloma virus)
infection. Cancer cells infected by HPV expressing a HPV protein called E6. E6 is the main
factors of HPV 16 carcinogenesis. In TCR-T therapy, researchers take the blood of a certain
patient, select T cells and insert genes into the cell that expressing a kind of protein that
targeting HPV E6. The genetically engineered cells are called E6 TCR-T cells. The engineered
cells are re-infused in the patients with cervical carcinoma.
Objective:
To evaluate the safety and efficacy of TCR-T cells in the treatment of cervical carcinoma.
Eligibility:
Adults aging 18-70 with relapsed/refractory to standard treatment or metastatic cervical
carcinoma.
Design:
Patients will have many screening tests, including imaging procedures, heart and lung tests,
and lab tests.
Patients will have leukapheresis. Blood will be removed through a needle in the arm. A
machine separates the white blood cells. The rest of the blood is returned through a needle
in the other arm.
Engineered T cells will be re-infused into the patients will stay in hospital and be
evaluated.